Recent Investment Analysts’ Ratings Changes for Jade Biosciences (JBIO)

by · The Cerbat Gem

Jade Biosciences (NASDAQ: JBIO) has recently received a number of price target changes and ratings updates:

  • 5/11/2026 – Jade Biosciences was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
  • 5/11/2026 – Jade Biosciences had its price target raised by Guggenheim from $23.00 to $32.00. They now have a “buy” rating on the stock.
  • 5/11/2026 – Jade Biosciences had its price target raised by Wedbush from $24.00 to $34.00. They now have an “outperform” rating on the stock.
  • 5/9/2026 – Jade Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
  • 4/27/2026 – Jade Biosciences had its price target raised by HC Wainwright from $35.00 to $45.00. They now have a “buy” rating on the stock.
  • 4/24/2026 – Jade Biosciences was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
  • 4/10/2026 – Jade Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 4/8/2026 – Jade Biosciences was upgraded by Zacks Research from “strong sell” to “hold”.
  • 3/25/2026 – Jade Biosciences had its price target raised by HC Wainwright from $25.00 to $35.00. They now have a “buy” rating on the stock.

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

Featured Stories